Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HCB101 |
Synonyms | |
Therapy Description |
HCB101 inhibits the CD47-SIRPa interaction, which potentially induces phagocytosis against tumor cells and inhibits tumor growth (J Immunother Cancer 2022;10(Suppl2):A496). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HCB101 | HCB-101|HCB 101 | HCB101 inhibits the CD47-SIRPa interaction, which potentially induces phagocytosis against tumor cells and inhibits tumor growth (J Immunother Cancer 2022;10(Suppl2):A496). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05892718 | Phase I | HCB101 | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPa-CD47 Pathway, in Solid or Hematological Tumors | Recruiting | USA | 1 |